# Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

> **NCT06679270** · PHASE3 · RECRUITING · sponsor: **Amryt Pharma** · enrollment: 24 (estimated)

## Conditions studied

- Familial Partial Lipodystrophy

## Interventions

- **DRUG:** Metreleptin

## Key facts

- **NCT ID:** NCT06679270
- **Lead sponsor:** Amryt Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2028-03
- **Final completion:** 2028-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06679270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06679270, "Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06679270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*